Comparative Pharmacology
Head-to-head clinical analysis: PREVACID NAPRAPAC 250 COPACKAGED versus RABEPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID NAPRAPAC 250 COPACKAGED versus RABEPRAZOLE SODIUM.
PREVACID NAPRAPAC 250 (COPACKAGED) vs RABEPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the gastric H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells, thereby suppressing basal and stimulated gastric acid secretion. It is a substituted benzimidazole that accumulates in the acidic environment of the parietal cell and is protonated, forming a covalent disulfide bond with cysteine residues of the proton pump, leading to irreversible inhibition.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
Oral: 20 mg once daily; duodenal ulcer: 20 mg once daily for up to 4 weeks; erosive esophagitis: 20 mg once daily for 4 to 8 weeks; GERD: 20 mg once daily for 4 to 8 weeks; Helicobacter pylori eradication: 20 mg twice daily in combination with antibiotics.
None Documented
None Documented
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
1-2 hours in most individuals, but pharmacodynamic half-life is longer (24-48 hours) due to irreversible binding to proton pumps; clearance is reduced in hepatic impairment (half-life up to 12 hours)
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Primarily renal (approx. 90% as metabolites, <1% unchanged) and fecal (approx. 10%)
Category C
Category A/B
Proton Pump Inhibitor/NSAID Combination
Proton Pump Inhibitor